16 results about "Lipid vesicle" patented technology

The present disclosure relates to compositions comprising phospholipids, lipid vesicles, and / or liposomes, and methods of use thereof. In one aspect, the present disclosure relates to methods and compositions for delivery of, biologically active lipids to reduce microvascular dysfunction and infarct size during revascularization of the blocked artery in a mammalian subject.

The present invention provides methods of introducing a molecule of interest into a lipid vesicle, such as an extracellular vesicle. The present invention provides lipid vesicles (e.g., extracellular vesicles) obtained using a method for introducing a molecule of interest into lipid vesicles (e.g., extracellular vesicles). According to the present invention, a complex of a lipid (e.g., an ionic lipid, in particular a liquid lipid composition) and a molecule of interest (a first complex) is fused with a lipid vesicle (e.g., an extracellular vesicle) to form a complex (a second complex). The first complex and the second complex are suitable for introducing a target molecule into a cell, and the second complex is particularly suitable for introducing a target molecule into a cell. The target molecule may be a protein (e.g., an antibody), a nucleic acid, or other compound.

Hair treatment compositions are disclosed. In some embodiments, the composition can include a first fraction of lipid vesicles encapsulating a first material and a second fraction of lipid vesicles encapsulating a second, different material. In some embodiments, the first material is a stimulant material, such as caffeine or green tea catechins, and the second material is a botanical bioactive material. The lipid vesicles can be plant-derived extracellular vesicles. In some embodiments, the composition comprises a base material with a non-encapsulated stimulant material and lipid vesicles that encapsulate a botanical bioactive material. The composition can also include three distinct carrier systems: lipid vesicles, liposomes, and ceramide complexes, each encapsulating a different bioactive material. These compositions can be formulated into products such as serums, masks, shampoos, or conditioners, which can be part of a multi-product hair care system.

Hair treatment compositions are disclosed. In some embodiments, the composition can include a first fraction of lipid vesicles encapsulating a first material and a second fraction of lipid vesicles encapsulating a second, different material. In some embodiments, the first material is a stimulant material, such as caffeine or green tea catechins, and the second material is a botanical bioactive material. The lipid vesicles can be plant-derived extracellular vesicles. In some embodiments, the composition comprises a base material with a non-encapsulated stimulant material and lipid vesicles that encapsulate a botanical bioactive material. The composition can also include three distinct carrier systems: lipid vesicles, liposomes, and ceramide complexes, each encapsulating a different bioactive material. These compositions can be formulated into products such as serums, masks, shampoos, or conditioners, which can be part of a multi-product hair care system.

This invention discloses a method for modifying lipid vesicles with an amphiphilic polymer containing N-oxide teramine groups. The amphiphilic polymer is OPDEA-PCL. OPDEA-PCL is used to modify synthetic liposomes, yielding amphiphilic polymer-synthetic liposome nanoparticles. OPDEA-PCL is also used to modify natural exosomes, yielding amphiphilic polymer-exosome nanoparticles. The amphiphilic polymer-synthetic liposomes of this invention possess active liver and lung targeting functions. This invention, through the engineered modification of exosomes with OPDEA-PCL, accurately guides exosomes to the liver regions requiring treatment, thereby enhancing the repair effect of exosomes on liver ischemia-reperfusion injury.

The invention relates to nanoparticles, nano eye drops as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a nanoparticle. The nanoparticle is composed of a tyrosine kinase inhibitor and a carrier protein, the mass ratio of the tyrosine kinase inhibitor to the carrier protein is (2-4): 1. The tyrosine kinase inhibitor-loaded nanoparticles are prepared and creatively combined with the photosensitizer-loaded lipid vesicles to obtain the synergistic photodynamic-VEGF inhibition difunctional photoresponsive nano eye drops which are uniform in particle size, simple and feasible in preparation method and good in stability; the photosensitizer and tyrosine kinase inhibitor co-delivery hydrogel prepared by the method realizes efficient co-delivery of the photosensitizer and the tyrosine kinase inhibitor, has a laser response release behavior, can be detained in eye tissues for a long time, not only greatly improves the bioavailability of hydrophobic drugs, but also realizes the final curative effect of resisting ocular angiogenesis, and has potential clinical application value.

The present invention is directed to formulations comprising a water-immiscible fluorocarbon solvent and at least one amphiphilic polymer, wherein the least one amphiphilic polymer is selected from a diblock co-polymer surfactant of formula A-B and a triblock co-polymer surfactant of formula B'-A'-B', wherein A and A' independently of each other represent a water-soluble polymer block having a weight average molecular weight in the range of 300 g / mol to 2000 g / mol, and B and B' represent independently of each other a perfluorinated polyether block having a weight average molecular weight in the range of 1500 g / mol to 7500 g / mol. Said formulations exhibit improved properties which render them particularly useful in droplet-based microfluidics applications, including the construction of lipid vesicles, cell encapsulation and monitoring, and droplet digital molecular biology.

The present application relates to a squeezing preparation method of the Caesalpinia minax lipid vesicle-like nanoparticles, comprising the following steps: mixing Caesalpinia minax and ultrapure water with a mass ratio of 1:6-1:10 to squeeze juice, then extruding the juice through a 100-200 mesh filter to obtain a Caesalpinia minax raw solution; then, gradient centrifuging the Caesalpinia minax raw solution to obtain a supernatant; finally, centrifuging the supernatant at a relative centrifugal force higher than the highest relative centrifugal force of the gradient centrifuging, then adding a standard phosphate buffer with a mass ratio of 1:8-1:10 to resuspend and precipitate, thereby obtaining the Caesalpinia minax lipid vesicle-like nanoparticles. The present application also provides the Caesalpinia minax lipid vesicle-like nanoparticles obtained by the method and the application of the Caesalpinia minax lipid vesicle-like nanoparticles in the treatment of ulcerative colitis. The present application overcomes the seasonal influence of the preparation of the existing tea lipid vesicle-like nanoparticles, greatly reduces the cost and controls the purity and quality, can solve the intestinal ecological imbalance problems such as mucosal epithelial repair and barrier homeostasis, has good safety and does not produce side effects, and is also a potential treatment for gastrointestinal disease treatment.

The present application is related to a pharmaceutical composition a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more surfactants; one or more compounds; and one or more penetration enhancing agents. The one or more penetration enhancing agents include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or combination with one or more penetration enhancing agents selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof. The present application is also related to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more polycationic surfactants; and one or more compounds.

The invention discloses lipid vesicles co-loading salvia miltiorrhiza-radix puerariae effective components, a preparation method and application, and the preparation method comprises the following steps: placing egg yolk lecithin, sodium deoxycholate, radix puerariae isoflavone, tanshinone and salvianolic acid in a round-bottom flask according to a weight ratio of 50: (22-27): 10: (0.3-0.9): 7, then adding methanol for fully dissolving, carrying out rotary evaporation under the conditions of 40 DEG C and 50 rpm / min, filtering, washing, and drying to obtain the lipid vesicles. Removing methanol to obtain a film; performing vacuum drying overnight at room temperature to obtain a dry and transparent film framework; adding ultrapure water into the membrane skeleton, and carrying out hydration treatment to obtain a liposome solution; and filtering the liposome solution with a 0.22 [mu] m cellulose acetate membrane to obtain the liposome. Through multi-component synergistic encapsulation, strong hydrophobic tanshinone is encapsulated in a phospholipid bilayer, weak hydrophobic pueraria isoflavone is distributed on a phospholipid layer or interface, and hydrophilic salvianolic acid is contained in a water phase or interface, so that the stability of a lipid vesicle system is enhanced, and the problem of low bioavailability of a preparation is solved.

The present invention relates to a liposome composition comprising brillaroxazine incorporated into bilayer lipid vesicles. In one embodiment, the liposome composition comprises bilayer lipid vesicles encapsulating an aqueous solution, wherein the bilayer lipid vesicles contain one or more phospholipids, sterols, and brillaroxazine, and the aqueous solution contains maltodextrin. The present invention also relates to a pharmaceutical composition comprising a brillaroxazine liposome composition and a pharmaceutically acceptable carrier.

The invention relates to the technical field of medicine, and discloses a nuciferine-based nano preparation for targeting digestive tract tumors and a preparation method thereof.The nuciferine-based nano preparation for targeting digestive tract tumors comprises nuciferine, 1, 2-dipalmitoyl-sn-glycerol-3-phosphatidylcholine, cholesterol, cholesterol hemisuccinate, 1, 2-dipalmitoyl-sn-glycerol-3-phosphatidylcholine, cholesterol hemisuccinate, 1, 2-dipalmitoyl-sn-glycerol-3-phosphatidylcholine, cholesterol hemisuccinate, 1 the lipid vesicle is composed of 1, 2-dioleoyl-sn-glycerol-3-phosphatidyl ethanolamine and distearoyl phosphatidyl ethanolamine-polyethylene glycol (2000)-cyclo (essence-glycerol-radix asparagi-styrene-acrylic-lysine) polypeptide, and the lipid vesicle is composed of 2, 2-dioleoyl-sn-glycerol-3-phosphatidyl ethanolamine and distearoyl phosphatidyl ethanolamine-polyethylene glycol (2000)- The preparation method of the nuciferine-based digestive tract tumor targeting nano preparation comprises the steps of film dispersion, hydration, high-pressure extrusion and purification. The active targeting effect of the cyclo (essence-glycerol-asparagi-styrene-acrylic-lysine) polypeptide ligand is utilized. Synergistic release of drugs in a tumor microenvironment is achieved, the targeting efficiency and local drug concentration of nuciferine are improved, and the anti-tumor effect is enhanced.

The present invention is directed to a liposome composition comprising brilaroxazine incorporated in bilayer lipid vesicles. In one embodiment, the liposome composition comprises bilayer lipid vesicles encapsulating an aqueous solution, wherein the bilayer lipid vesicles comprise one or more phospholipids, sterol, and brilaroxazine, and the aqueous solution comprises maltodextrin. The present invention is also directed to a pharmaceutical composition comprising the brilaroxazine liposome composition and a pharmaceutically acceptable carrier.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical preparation for improving premature ovarian failure and a preparation method thereof. The pharmaceutical preparation comprises the following raw materials in parts by weight: drug-loaded lipid vesicles 10-30 parts, cell membrane suspension 2000 parts, and freeze-drying protective agent 10 parts. The responsive inner core is constructed by cross-linking natural polysaccharide and thioether diamine, and efficiently loads rh-bFGF. The fusion membrane is constructed by the liposome modified with FSHB targeting peptide and the ovary granulosa cell membrane, and realizes the coating of melatonin. The fusion membrane has homologous and active double targeting capabilities, can intelligently depolymerize and release drugs under the local high oxidative stress microenvironment of the ovary, and can efficiently and safely improve and repair the damaged ovarian function through the multi-dimensional synergistic effect of ROS clearance, natural polysaccharide activity and microvascular regeneration promotion.

The present application relates to a kind of nanoparticles, nano drop eye drops and its preparation method and application, belong to medical technology field.The present application provides a kind of nanoparticle, the nanoparticle is composed of tyrosine kinase inhibitor and carrier protein;The mass ratio of tyrosine kinase inhibitor and carrier protein is 2~4:1.The present application prepares a kind of nanoparticle loaded tyrosine kinase inhibitor, creatively combines it with light-sensitive agent loaded lipid vesicle, obtains a kind of synergistic photodynamic-VEGF inhibits bifunctional light-responsive nano drop eye drops, its particle size is uniform, preparation method is simple and easy to operate, and stability is good, realizes the efficient co-delivery of light-sensitive agent, tyrosine kinase inhibitor, with laser response release behavior, and can be long time in eye tissue Retention, not only greatly improve the bioavailability of hydrophobic drug, and realize the final curative effect of anti-ocular angiogenesis, with potential clinical application value.